Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Healthcare and medical technology company Johnson & Johnson (JNJ) has reported first-quarter financial results that beat Wall ...

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally promoting the HIV drugs ...

Reese Marketos played the role of government prosecutor in a False Claims Act case about alleged off-label use of an HIV drug ...

Johnson & Johnson (NYSE:JNJ), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, beating the consensus of $2.60. The pharmaceutical giant reported sales of $ ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

Q1 adjusted EPS of $2.77 beat estimates; cancer drug Darzalex sales jumped 20.3% ... % or 4.2 operationally to $13.90 billion. Also Read: Johnson & Johnson, Protagonist Tout Positive Results ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

The Dark Secrets of Johnson & Johnson.” Erythropoietin — also known as EPO — is mostly remembered as the drug that cyclist Lance Armstrong dishonestly used to win seven Tours de France.

Johnson & Johnson announced compelling results ... These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap ...

If the FDA approves nipocalimab, the long-term data could form part of J&J’s pitch for the gMG market. The labels for ...